Table 2.
Characteristics of included studies on serum 25 (OH) D level between AD patients and healthy controls.
| Study | Year | Study population age (AD group/control group) (years) | Study size | Location |
|---|---|---|---|---|
| Lipińska et al. | 2021 | Median age (7/8) | 75 cases, 37control subjects | Poland |
| Ahmed et al. | 2021 | Mean age (11/9.2) | 100 cases, 101 control subjects | Egypt |
| Sanmartin et al. | 2020 | Age range (0-12/0-12) | 134 cases, 105 control subjects | Spain |
| Xiang et al. | 2019 | Mean age (5.1/3.2) | 81 cases, 65 control subjects | China |
| Lee et al. | 2019 | Mean age (8.6/9.4) | 135 cases, 65 control subjects | Malaysia |
| Daniluk et al. | 2019 | Median age (6/5.5) | 29 cases, 22 control subjects | Poland |
| Machura et al. | 2018 | Age range (2-14/2-14) | 57 cases, 34 control subjects | Poland |
| Dogru et al. | 2018 | Mean age (5.6/5.4) | 69 cases, 70 control subjects | Turkey |
| Su et al. | 2017 | Mean age (6.5/7.4) | 60 cases, 37 control subjects | Turkey |
| D'Auria et al. | 2017 | Mean age (6.2/6.1) | 52 cases, 43 control subjects | Italy |
| Sharma et al. | 2017 | Mean age (6.1/6.7) | 40 cases, 40 control subjects | India |
| Cheon et al. | 2015 | Median age (6/6) | 91 cases, 32 control subjects | Korea |
| Wang et al. | 2014 | Median age (6/5.5) | 498 cases, 328 control subjects | Hong Kong |
| El Taieb et al. | 2013 | Mean age (6.1/6.5) | 29 cases, 30 control subjects | Egypt |